In acute B-lymphoblastic leukemia (B-ALL), García-Aguilera et al. (2024) described a 23-color panel that identified CD19-negative leukemic clones—a critical challenge following CD19-targeted therapies [22]. Here, CD19 is linked to precursor B-cell acute lymphoblastic leukemia.